Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals Kicks Off Phase 1 Clinical Trial for Experimental COVID-19 Vaccine

By Prosper Junior Bakiny – Apr 6, 2020 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The early study will only test whether INO-4800 is safe and triggers an immune response.

Inovio Pharmaceuticals (INO 6.02%) has been moving fast in the race to develop a vaccine for COVID-19. The company claimed it had created a potential vaccine for the rapidly spreading coronavirus on Jan. 10, just three hours after Chinese researchers publicly released the genetic sequence of SARS-CoV-2 the virus that causes the illness. Now, it's starting human clinical trials for that potential vaccine, INO-4800. 

The trial will involve up to 40 healthy adult volunteers, each of whom will receive two doses of INO-4800 four weeks apart. The goals of the phase 1 trial are to test the vaccine's safety and its immunogenicity --i.e., its ability to trigger an immune response in the body. Inovio expects initial data from this trial by late summer, and plans to move on to phase 2 clinical trials -- which will test INO-4800's efficacy -- as soon as possible.

Microscopic view of Coronavirus cells.

Image Source: Getty Images.

Other companies are also making headway in their efforts to develop a vaccine for COVID-19. For instance, pharma giant Johnson & Johnson (JNJ -0.46%) recently announced that it would initiate human clinical trials for its investigational COVID-19 vaccine by September. Moderna (MRNA 2.12%) arguably remains the leader in this race. The National Institutes of Health (NIH) is currently leading a phase 1 clinical trial of Moderna's COVID-19 vaccine candidate. This trial, which will involve up to 45 healthy adult volunteers, will test the vaccine's safety, immunogenicity, and its reactogenicity (the amount of it that causes expected side effects).

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.76 (6.02%) $0.10
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$164.94 (-0.46%) $0.76
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$122.23 (2.12%) $2.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.